WEBULL

Assessing Masimo (MASI) Valuation As Shares Trade Below Popular Undervalued Fair Value Narrative

Simply Wall St · 01/08 19:38

With no single headline event driving attention today, Masimo (MASI) is on investors’ radars as a medical technology maker with mixed return figures, as well as recent revenue and net income trends that invite closer scrutiny.

See our latest analysis for Masimo.

Masimo’s recent share price moves have been choppy, with a 7-day share price return of 5.4%, a 30-day share price return decline of 2.68%, and a 1-year total shareholder return loss of 18.79%, suggesting that short-term momentum contrasts with weaker longer-term outcomes around its US$137.08 level.

If Masimo’s mixed track record has you reassessing your watchlist, this can be a useful moment to scan other healthcare stocks that may better fit your risk and return expectations.

With the share price sitting around US$137.08, a value score of 2, and a market view that implies roughly a 34% discount to analyst targets, the key question is whether Masimo is genuinely undervalued or whether the market already reflects its future potential.

Most Popular Narrative Narrative: 25.1% Undervalued

Compared with Masimo’s last close at US$137.08, the most followed narrative points to a higher fair value of about US$183, framing the stock as materially mispriced on current assumptions.

The expansion of dedicated specialty sales teams and realignment of the commercial structure is expected to drive increased market share in high-growth categories like capnography, brain monitoring, and hemodynamics, where current share is below 20%, which should accelerate top-line revenue growth and elevate long-term earnings.

Ongoing innovation including next-gen monitors featuring advanced AI algorithms and redeployment of novel sensor technologies positions Masimo to command premium pricing and capture greater value as hospitals prioritize technologically advanced, multiparameter solutions, supporting both revenue expansion and improved gross margins.

Read the complete narrative.

Curious what earnings path and margin profile sit behind that higher fair value, and what kind of future P/E multiple ties it all together? The full narrative spells out how revenue trends, profitability shifts, and valuation math connect to that US$183 figure, and which assumptions have the biggest impact if they change.

Result: Fair Value of $183.13 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there are still clear pressure points, including exposure to shifting tariffs and dependence on lumpy hospital and OEM contracts, that could disrupt this upbeat earnings story.

Find out about the key risks to this Masimo narrative.

Another Take: What The Price-To-Sales Ratio Is Saying

That US$183 fair value narrative leans on future earnings and margins, but today the market is setting Masimo’s price using revenue. At around 3.4x P/S, the shares sit above the US Medical Equipment industry at 3.1x and well above a fair ratio of 1.5x.

In plain terms, the market is already paying a richer multiple than both peers and the level our fair ratio suggests the stock could gravitate toward. This raises the question: is sentiment running ahead of fundamentals, or are analysts underestimating the long term story?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:MASI P/S Ratio as at Jan 2026
NasdaqGS:MASI P/S Ratio as at Jan 2026

Build Your Own Masimo Narrative

If you see the numbers differently or want to stress test your own assumptions, it only takes a few minutes to build a custom story: Do it your way.

A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Masimo.

Looking for more investment ideas?

If Masimo has sharpened your thinking, do not stop here. Use the Simply Wall St screener to line up fresh ideas that better match your style and goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.